T. Rowe Price Investment Management’s NovoCure NVCR Stock Holding History

T. Rowe Price Investment Management’s Portfolio NVCR Stock Details NVCR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$10.1M	Buy	927,382 +924,239	+29,406%	+$11.5M	0.01%	536
2025 Q4	$41K	Sell	3,143 -942,283	-100%	-$12.1M	﹤0.01%	672
2025 Q3	$12.2M	Buy	945,426 +227,371	+32%	+$3.04M	0.01%	546
2025 Q2	$12.8M	Buy	+718,055	New	+$12.5M	0.01%	539
2025 Q1	–	Sell	-1,690,441	Closed	-$50.4M	–	687
2024 Q4	$50.4M	Sell	1,690,441 -1,115,692	-40%	-$23.6M	0.03%	407
2024 Q3	$43.9M	Buy	2,806,133 +1,093,740	+64%	+$19.8M	0.03%	422
2024 Q2	$29.3M	Buy	+1,712,393	New	+$30.1M	0.02%	461
2023 Q3	–	Sell	-1,890,836	Closed	-$78.5M	–	587
2023 Q2	$78.5M	Buy	1,890,836 +312,351	+20%	+$19.4M	0.05%	307
2023 Q1	$94.9M	Buy	1,578,485 +1,533,426	+3,403%	+$123M	0.07%	268
2022 Q4	$3.31M	Buy	+45,059	New	+$3.39M	﹤0.01%	530

Other funds holding NVCR

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

SCM

Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

QCM

Quantinno Capital Management New York $59.9B AUM 28.07% 1-Year Est. Return

T. Rowe Price Investment Management's NVCR Position: Q1 2026 in Review

T. Rowe Price Investment Management increased its NovoCure (NVCR) stake by 29,406% in Q1 2026, buying an estimated $11.5M and bringing the position to 927,382 shares worth $10.1M. The position accounts for 0.01% of the portfolio, ranked #536.

T. Rowe Price Investment Management first reported a position in NVCR in Q4 2022 and has held it in 10 quarters since. The position peaked at $94.9M in Q1 2023. 223 funds tracked by Wall St. Rank hold NVCR as of Q1 2026.

T. Rowe Price Investment Management held 927,382 shares of NovoCure worth $10.1M as of Q1 2026.
T. Rowe Price Investment Management bought 924,239 NovoCure shares in Q1 2026, an estimated $11.5M.
NovoCure made up 0.01% of T. Rowe Price Investment Management's portfolio in Q1 2026, its #536 holding.
T. Rowe Price Investment Management first reported a position in NovoCure in Q4 2022 and has held it in 10 quarters since.
T. Rowe Price Investment Management's NovoCure position peaked at $94.9M in Q1 2023.
223 funds tracked by Wall St. Rank held NovoCure as of Q1 2026.

Based on T. Rowe Price Investment Management's 13F filing for Q1 2026, filed 15 May 2026.